Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Farmers Insurance
Teva
Merck
Covington
Cipla
Baxter
Chubb
Colorcon

Generated: February 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

« Back to Dashboard

Clinical Trials for Insulin Zinc Susp Extended Recombinant Human

Trial ID Title Status Sponsor Phase Summary
NCT00000110 Influence of Diet and Endurance Running on Intramuscular Lipids Measured at 4.1 TESLA Completed National Center for Research Resources (NCRR) N/A The purpose of this pilot investigation is to use 1 H Magnetic Resonance Spectroscopy (MRS) to 1) document the change in intra-muscular lipid stores (IML) before and after a prolonged bout of endurance running and, 2) determine the pattern (time course) of IML replenishment following an extremely low-fat diet (10% of energy from fat) and a moderate-fat diet (35% of energy from fat). Specifically, the study will evaluate the change in IML following a 2-hour training run and the recovery of IML in response to the post-exercise low-fat or moderate-fat diet in 10 endurance trained athletes who will consume both diets in a randomly assigned cross-over fashion. We hypothesize that IML will be depleted with prolonged endurance exercise, and that replenishment of IML will be impaired by an extremely low-fat diet compared to a moderate-fat diet. Results of this pilot study will be used to apply for extramural grant support from NIH or the US Armed Forces to investigate the effect of dietary fat on the health and performance of individuals performing heavy physical training. It is anticipated that this methodology could also be employed in obesity research to delineate, longitudinally, the reported cross-sectional relationships among IML stores, insulin resistance and obesity.
NCT00000159 Sorbinil Retinopathy Trial (SRT) Completed National Eye Institute (NEI) Phase 3 To evaluate the safety and efficacy of the investigational drug sorbinil, an aldose reductase inhibitor, in preventing the development of diabetic retinopathy and neuropathy in persons with insulin-dependent diabetes.
NCT00000380 Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep Disturbances Completed National Institute of Mental Health (NIMH) N/A The purpose of this study is to examine the effects of giving growth hormone releasing hormone (GHRH) to treat sleep disorders in older men and in older women who are on estrogen replacement therapy (ERT). Many older men and women complain of sleep disturbances. GHRH has been used successfully to treat sleep disorders in young men and may help older men and women. 40 healthy older men and 40 healthy older women on ERT will receive either GHRH or an inactive placebo. An individual may be eligible for this study if he/she is a healthy older man or woman with sleep disturbances, and is on estrogen replacement therapy (women).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Insulin Zinc Susp Extended Recombinant Human

Condition Name

Condition Name for Insulin Zinc Susp Extended Recombinant Human
Intervention Trials
Diabetes Mellitus, Type 2 588
Diabetes 567
Type 2 Diabetes Mellitus 343
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Insulin Zinc Susp Extended Recombinant Human
Intervention Trials
Diabetes Mellitus 2006
Diabetes Mellitus, Type 2 1305
Diabetes Mellitus, Type 1 668
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Insulin Zinc Susp Extended Recombinant Human

Trials by Country

Trials by Country for Insulin Zinc Susp Extended Recombinant Human
Location Trials
Hungary 96
Czech Republic 91
Finland 91
Taiwan 86
Puerto Rico 86
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Insulin Zinc Susp Extended Recombinant Human
Location Trials
California 564
Texas 515
New York 394
Florida 371
Pennsylvania 314
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Insulin Zinc Susp Extended Recombinant Human

Clinical Trial Phase

Clinical Trial Phase for Insulin Zinc Susp Extended Recombinant Human
Clinical Trial Phase Trials
Phase 4 1089
Phase 3 758
Phase 2/Phase 3 118
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Insulin Zinc Susp Extended Recombinant Human
Clinical Trial Phase Trials
Completed 2441
Recruiting 657
Unknown status 339
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Insulin Zinc Susp Extended Recombinant Human

Sponsor Name

Sponsor Name for Insulin Zinc Susp Extended Recombinant Human
Sponsor Trials
Novo Nordisk A/S 511
Sanofi 246
Eli Lilly and Company 186
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Insulin Zinc Susp Extended Recombinant Human
Sponsor Trials
Other 3883
Industry 2134
NIH 532
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Chubb
Farmers Insurance
McKesson
Baxter
Mallinckrodt
Cantor Fitzgerald
Johnson and Johnson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.